Inhibition of EWS-FLI-1 fusion protein with antisense oligodeoxynucleotides

Journal of Neuro-Oncology

Volumn 31, Issue 1-2, 1997, Pages 09-16

  Toretsky, Jeffrey A ^a,b   Connell, Yvette ^b   Neckers, Len ^b   Bhat, Narayan K ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SAIC FREDERICK INC   (United States)

Author keywords

Antisense; Ewing's sarcoma; FLI; Oligodeoxynucleotide; Translocation

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CHIMERIC PROTEIN; HYBRID PROTEIN; MESSENGER RNA; RIBONUCLEASE H;

ARTICLE; CELL FREE SYSTEM; CELL VIABILITY; CHROMOSOME 11Q; CHROMOSOME 22Q; CONTROLLED STUDY; ELECTROPORATION; EWING SARCOMA; GENE EXPRESSION; GENE FUSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PHENOTYPE; RECIPROCAL CHROMOSOME TRANSLOCATION; RNA TRANSLATION; TRANSLATION REGULATION;

EID: 0031040025     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1005716926800     Document Type: Article

References (23)

1. Akhtar S: Delivery strategies for antisense oligonucleotide therapeutics. CRC Press, Inc., Boca Raton, FL, 1995
2. Bailly RA, Bosselut R, Zucman J, Cormier F, Delattre O, Roussel M, Thomas G, Ghysdael J: DNA-binding and tran-scriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma. Mol Cell Biol 14: 3230, 1994
3. Bergan R, Connell Y, Fahmy B, Kyle E, Neckers L: Aptameric inhibition of p210bcr-abl tyrosine kinase autophosphorylation by oligodeoxynucleotides of defined sequence and backbone structure. Nucleic Acids Res 22: 2150, 1994
4. Bergan R, Connell Y, Fahmy B, Neckers L: Electroporation enhances c-myc antisense oligodeoxynucleotide efficacy. Nucleic Acids Res 21: 3567, 1993
5. Bhat NK: P.T.S. Characterization and uses of monoclonal antibody derived against DNA binding domain of the ETS family of genes. Hybridoma 11: 277, 1992
6. Boiziau C, Larrouy B, Moreau S, Cazenave C, Shire D, Toulme JJ: Ribonuclease II-mediated inhibition of translation and reverse transcription by antisense oligodeoxynucleotides. Biochem Soc Trans 20: 764, 1992
7. Braun B, Frieden R, Lessnick S, May W, Denny C: Identification of Target Genes for the Ewing's Sarcoma EWS/FLI Fusion Protein by Representational Difference Analysis. Mol Cell Biol 15: 4623, 1995
8. Chen H, Gold L: Selection of high-affinity RNA ligands to reverse transcriptase: inhibition of cDNA synthesis and RNase H activity. Biochemistry 33: 8746, 1994
9. Damha MJ, Giannaris PA, Marfey P: Antisense L/D-oligodeoxynucleotide chimeras: nuclease stability, base-pairing properties, and activity at directing ribonuclease H. Biochemistry 33: 7877, 1994
10. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, Kovar H, Joubert I, de JP, Rouleau G: Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359: 162, 1992
11. Dunn T, Praissman L, Hagag N, Viola MV: ERG gene is translocated in an Ewing's sarcoma cell line. Cancer Genet Cytogenet 76: 19, 1994
12. Kitada S, Miyashita T, Tanaka S, Reed JC: Investigations of antisense oligonucleotides targeted against bcl-2 RNAs. Antisense Res Dev 3: 157, 1993
13. Mao X, Miesfeldt S, Yang H, Leiden JM, Thompson CB: The FLI-1 and chimeric EWS-FLI-1 oncoproteins display similar DNA binding specificities. J Biol Chem 269: 18216, 1994
14. May WA, Gishizky ML, Lessnick SL, Lunsford LB, Lewis BC, Delattre O, Zucman J, Thomas G, Denny CT: Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci USA 90: 5752, 1993
15. May WA, Lessnick SL, Braun BS, Klemsz M, Lewis BC, Lunsford LB, Hromas R, Denny CT: The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol 13: 7393, 1993
16. Peter M, Magdelenat H, Michon J, Melot T, Oberlin O, Zucker JM, Thomas G, Delattre O: Sensitive detection of occult E wing's cells by the reverse transcriptase-polymerase chain reaction. Br J Cancer 72: 96, 1995
17. Plougastel B, Zucman J, Peter M, Thomas G, Delattre O: Genomic structure of the EWS gene and its relationship to EWSR1, a site of tumor-associated chromosome translocation. Genomics 18: 609, 1993
18. Rao VN, Ohno T, Prasad DD, Bhattacharya G, Reddy ES: Analysis of the DNA -binding and transcriptional activation functions of human Fli-1 protein. Oncogene 8: 2167, 1993
19. Sakakura C, Yamaguchi-Iwai Y, Satake M, Bae SC, Takahashi A, Ogawa E, Hagiwara A, Takahashi T, Murakami A, Makino K: Growth inhibition and induction of differentiation of t(8;21) acute myeloid leukemia cells by the DNA-binding domain of PEBP2 and the AML1/MTG8(ETO)-specific antisense oligonucleotide. Proc Natl Acad Sci USA 91: 11723, 1994
20. Skorski T, Nieborowska-Skorska M, Nicolaides NC, Szczylik C, Iversen P, Iozzo RV, Zon G, Calabretta B: Suppression of Philadelphial leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide. Proc Natl Acad Sci USA 91: 4504, 1994
21. Sorensen PH, Lessnick SL, Lopez TD, Liu XF, Triche TJ, Denny CT: A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 6: 146, 1994
22. Toretsky JA, Neckers L, Wexler LH: Detection of (11;22) (q24;q12) translocation-bearing cells in peripheral blood progenitor cells of patients with Ewing's sarcoma family of tumors. J Natl Cancer Inst 87: 385, 1995
23. Whang PJ, Triche TJ, Knutsen T, Miser J, Kao SS, Tsai S, Israel MA: Cytogenetic characterization of selected small round cell tumors of childhood. Cancer Genet Cytogenet 21: 185, 1986